Document Detail


Transradial Palmaz-Schatz coronary stenting on an outpatient basis: results of a prospective pilot study.
MedLine Citation:
PMID:  10155117     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The applicability of Palmaz Schatz coronary stent implantation is limited by bleeding complications and prolonged hospitalization. Coronary stenting on an outpatient basis, may be the ultimate means to reduce costs of this treatment. Since bleeding and stent occlusion were infrequent complications in a group of 100 ambulatory patients who underwent stent implantation via the radial artery in our department, we performed a pilot study to determine the feasibility of using coronary stenting on an outpatient basis. METHODS: Patients selected for Palmaz Schatz stent implantation, were adequately adjusted on coumadin. At an INR > 2.5, stenting was performed via the radial approach. Based on pre-, post- and procedural criteria, considering clinical status, procedural course and outcome, absence of predictors for stent occlusion and of events during 4 to 6 hours observation, patients were considered candidates for same-day discharge. Heparin was administered only during the procedure. Immediately after the procedure, the arterial sheath was removed. Patients were mobilized and were discharged with a pressure dressing over the puncture site. Follow-up was performed on the next day, at 2 weeks and at one month. RESULTS: Between May and September 1994, 47 patients underwent Palmaz Schatz stent implantation via the radial artery. Of these, 27 remained hospitalized for reasons, considered to be incompatible with outpatient treatment. Twenty patients (CCS-class III and IV; n = 17 (85%)) received 29 stents for 23 lesions, distributed in 21 vessels and were discharged the day of treatment. No cardiac or bleeding events were encountered within 24 hours. At 2 weeks follow-up, one patient was readmitted (day 4) because of a bleeding abdominal aortic aneurysm, requiring surgery. At 1 month follow-up, no bleeding, entry-site and cardiac complications were noted. CONCLUSION: Since no complications were encountered (95% confidence interval; 0-17%) in the first 24 hours after optimal coronary stent implantation in patients with an adequate preprocedural level of anticoagulation, a larger feasibility study of outpatient coronary stenting will be undertaken.
Authors:
F Kiemeneij; G J Laarman; T Slagboom; P Stella
Related Documents :
19508977 - Percutaneous coronary interventions affect concentrations of interleukin 6 and its solu...
17060387 - Randomized study on simple versus complex stenting of coronary artery bifurcation lesio...
10856387 - Predictors of clinical outcome following percutaneous intervention for in-stent resteno...
12623597 - Clinical trends in stent treatment of simple and complex coronary disease.
16022957 - Reduced systemic arterial compliance impacts significantly on left ventricular afterloa...
18498767 - Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patien...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of invasive cardiology     Volume:  7 Suppl A     ISSN:  1042-3931     ISO Abbreviation:  J Invasive Cardiol     Publication Date:  1995  
Date Detail:
Created Date:  1995-11-06     Completed Date:  1995-11-06     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8917477     Medline TA:  J Invasive Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  5A-11A     Citation Subset:  T    
Affiliation:
Amsterdam Department of Interventional Cardiology (ADIC)-OLVG, the Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Ambulatory Care*
Anticoagulants / therapeutic use
Coronary Disease / therapy*
Cost Control
Equipment Design
Feasibility Studies
Female
Follow-Up Studies
Heparin / therapeutic use
Humans
Male
Middle Aged
Pilot Projects
Prospective Studies
Radial Artery*
Stents*
Warfarin / therapeutic use
Chemical
Reg. No./Substance:
0/Anticoagulants; 81-81-2/Warfarin; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  New challenges in coronary stenting.
Next Document:  Use of the perfusion balloon as a primary dilation device.